◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › R › RLMD

Relmada Therapeutics Inc (RLMD) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-10-02

Relmada Therapeutics Inc (RLMD) operates in the BIOTECHNOLOGY industry and is headquartered in Coral Gables, United States with about 17 employees. Its market capitalization is roughly $382 million. In the fiscal year ended 2025-12-31, RLMD reported $0M in revenue and ($57M) in net income.

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.

Interactive charts & full statements →

RLMD Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Total Revenue	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	$0M	—	—	—	—	$0M	$0M
Gross Profit	—	—	—	—	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	$0M	$0M
Gross Margin %	—	—	—	—	—	—	—	—	—	—	—	—	—	21.3%	27.0%
Operating Income (EBIT)	($65M)	($59M)	($84M)	($104M)	($161M)	($126M)	($61M)	($15M)	($7M)	($7M)	($16M)	($17M)	($17M)	$0M	$0M
Operating Margin %	—	—	—	—	—	—	—	—	—	—	—	—	—	-877.7%	-151.8%
Net Income	($62M)	($57M)	($80M)	($99M)	($157M)	($126M)	($59M)	($15M)	($9M)	($6M)	($3M)	($21M)	($21M)	$0M	$0M
Net Margin %	—	—	—	—	—	—	—	—	—	—	—	—	—	-877.7%	-151.8%
EBITDA	($62M)	($57M)	($80M)	$5M	($157M)	($126M)	($59M)	($15M)	($7M)	($7M)	($16M)	($17M)	($21M)	$0M	$0M
Earnings Per Share (EPS)	$-0.55	$-1.45	$-2.65	$-3.28	$-5.30	$-7.16	$-3.81	$-1.63	$-2.86	$-2.08	$-1.03	$-8.37	$-8.37	$-0.00	$-0.00
Shares Outstanding (M)	112M	39M	30M	30M	30M	18M	16M	9M	3M	3M	3M	2M	—	—	3M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RLMD Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Gross Profit	—	—	—	—	—	—	—	—
Operating Income (EBIT)	($15M)	($19M)	($20M)	($10M)	($10M)	($18M)	($19M)	($23M)
Operating Margin %	—	—	—	—	—	—	—	—
Net Income	($13M)	($19M)	($20M)	($10M)	($10M)	($18M)	($19M)	($22M)
Net Margin %	—	—	—	—	—	—	—	—
EBITDA	($13M)	($19M)	($20M)	($10M)	($10M)	($18M)	$0M	$1M
Earnings Per Share (EPS)	$-0.11	$-0.22	$-0.29	$-0.30	$-0.30	$-0.58	$-0.62	$-0.72
Shares Outstanding (M)	112M	87M	68M	33M	33M	30M	30M	30M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RLMD Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2014-06-30	2013-12-31	2012-12-31
Cash from Operations (CFO)	($46M)	($46M)	($52M)	($52M)	($104M)	($92M)	($28M)	$0M	($6M)	($6M)	($13M)	($16M)	($16M)	($2M)	$0M	$0M
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$1M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($46M)	($46M)	($52M)	($52M)	($104M)	($92M)	($28M)	$0M	($6M)	($7M)	($14M)	($16M)	($16M)	($2M)	$0M	$0M
FCF Margin %	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-266.3%	-95.3%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RLMD Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($10M)	($15M)	($15M)	($7M)	($6M)	($18M)	($9M)	($17M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($10M)	($15M)	($15M)	($7M)	($6M)	($18M)	($9M)	($17M)
FCF Margin %	—	—	—	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RLMD Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2014-06-30	2013-12-31	2012-12-31
Total Assets	$219M	$94M	$46M	$98M	$153M	$223M	$118M	$117M	$3M	$3M	$10M	$24M	$24M	$26M	$26M	$0M
Cash & Cash Equivalents	$11M	$3M	$4M	$4M	$5M	$44M	$2M	$36M	$2M	$2M	$9M	$22M	$22M	$26M	$26M	$0M
Total Liabilities	$13M	$7M	$10M	$12M	$12M	$15M	$13M	$1M	$9M	$1M	$3M	$16M	$16M	$27M	$27M	$0M
Total Debt (Short + Long-Term)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$3M	$0M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$207M	$87M	$36M	$85M	$140M	$208M	$106M	$116M	($6M)	$1M	$7M	$9M	$9M	($1M)	($55M)	$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RLMD viewer.

Other Companies in BIOTECHNOLOGY

ALLO · Allogene Therapeutics Inc — $408 million
ALT · Altimmune Inc — $397 million
ZURA · Zura Bio Limited Class A Ordinary Shares — $389 million
TECX · Tectonic Therapeutic, Inc. — $387 million
MPLT · MapLight Therapeutics, Inc. Common Stock — $378 million
AUTL · Autolus Therapeutics Ltd — $377 million
AGMB · AgomAb Therapeutics NV American Depositary Shares — $369 million
CTNM · Contineum Therapeutics, Inc. Class A Common Stock — $365 million

← RLI All “R” companies RLRE →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.